Video

Expert on PSMA-PET: "It's just simply better"

Author(s):

Urology Times staff
Conference|LUGPA Annual Meeting

"What we know for sure is [PSMA-PET is] just simply better imaging in terms of accuracy," says Ashley Ross, MD, PhD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Ashley Ross, MD, PhD, associate professor of Urology and the clinical director of the Polsky Urologic Cancer Institute at Northwestern University, discusses the emergence of PSMA-PET in prostate cancer. Ross was speaking at the 2022 LUGPA Annual Meeting in Chicago, Illinois.

      Related Videos
      Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
      Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Amy Krambeck, MD, on innovation and building strong programs in endourology
      Amy Krambeck, MD, on innovation and building strong programs in endourology
      Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
      Expert discusses the NMIBC trials landscape
      5 key trial insights from AUA 2025
      5 key trial insights from AUA 2025
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      Endourologist discusses shared decision-making and laser lithotripsy
      Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
      Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
      Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
      Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
      Kevin Zorn, MD, on preserving ejaculation with BPH therapies
      Kevin Zorn, MD, on preserving ejaculation with BPH therapies
      Related Content
      US Capitol building | Image Credit: © sherryvsmith - stock.adobe.com
      May 6th 2025

      AUA Advocacy Summit: Medicare payment reform among top priorities

      Jennifer Miles-Thomas, MD, URPS, MBA Benjamin P. Saylor
      Jennifer Miles-Thomas, MD, URPS, MBA, discusses the AUA's legislative priorities along with issues in medicine related to artificial intelligence.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Hugo robot-assisted surgery system shows promise for urologic procedures
      May 2nd 2025

      Hugo robot-assisted surgery system shows promise for urologic procedures

      Hannah Clarke
      These results are expected to support submission of the Hugo system to the FDA for use in urologic procedures.
      Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
      April 30th 2025

      Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

      Amy M. Pearlman, MD Ryan Terlecki, MD
      A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
      CISTO: Radical cystectomy has key role in recurrent high-grade NMIBC
      May 1st 2025

      CISTO: Radical cystectomy has key role in recurrent high-grade NMIBC

      Hannah Clarke
      Twelve-month physical functioning scores were comparable between the radical cystectomy arm and the bladder-sparing therapy arm.
      TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
      April 30th 2025

      TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

      Hannah Clarke
      Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
      © 2025 MJH Life Sciences

      All rights reserved.